Predictors of damage accrual and its impact on health-related quality of life of thrombotic antiphospholipid syndrome: Independent validation of the damage index for antiphospholipid syndrome (DIAPS)

被引:1
作者
Gaspar, Pedro [1 ,2 ,7 ]
Fernandes, Ana Sofia M. [3 ]
Abrantes, Ana Mafalda [1 ,4 ]
Parreira, Ines [1 ]
Silva, Ines [1 ]
Silva, Ryan C. [1 ,5 ]
Nobre, Mariana B. [1 ]
Martins, Joana R. [1 ,5 ]
Mota, Catarina [2 ,6 ]
机构
[1] Hosp Santa Maria, Internal Med Dept, Unidade Local Saude Santa Maria, Lisbon, Portugal
[2] Univ Lisbon, Fac Med, Ctr Acad Med Lisboa, Inst Med Mol Joao Lobo Antunes, Lisbon, Portugal
[3] Hosp Geral Santo Antonio, Unidade Local Saude Porto, Porto, Portugal
[4] Univ Lisbon, Fac Med, Inst Semiot Clin, Lisbon, Portugal
[5] Univ Lisbon, Fac Med, Clin Univ Med 1, Lisbon, Portugal
[6] Univ Lisbon, Fac Med, Clin Univ Med 2, Lisbon, Portugal
[7] Univ Lisbon, Fac Med, Inst Med Mol Joao Lobo Antunes, Edificio Egas Moniz,Av Prof Egas Moniz, P-1649028 Lisbon, Portugal
关键词
Antiphospholipid syndrome; damage index; damage index for antiphospholipid syndrome; organ damage; quality of life; IMPAIRMENT;
D O I
10.1177/09612033241246360
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objectives We aim to independently assess the validity of the damage index for antiphospholipid syndrome (DIAPS) in thrombotic antiphospholipid syndrome (APS) patients by exploring the prevalence and risk factors of organ damage and evaluating its impact on health-related quality of life (HR-QoL).Methods Cross-sectional study including all thrombotic APS patients (Sydney criteria) attending a Portuguese tertiary centre. Damage was assessed using the DIAPS, and HR-QoL using the 3- and 5-level EuroQol HR-QoL (EQ-D5-3L and 5L), and Visual Analogue Scale (VAS) applied via a phone questionnaire. Spearman's correlation between DIAPS and the HR-QoL scales was performed. Risk factors for damage accrual and HR-QoL impairment were explored using univariate and multivariate logistic regression.Results Among the 108 patients (female, 65.7%; white, 90.7%; primary APS, 75.9%; median disease duration, 6 years), damage (DIAPS >= 1) developed in 48.2% of patients (mean +/- SD DIAPS, 3.08 +/- 1.83). DIAPS's neuropsychiatric domain was the most affected (24.2%), followed by the peripheral vascular domain (20.3%). No clinical, demographic nor laboratory parameters were significantly associated with damage. Regarding HR-QoL, pain/discomfort, anxiety/depression and usual activities domains were the most frequently impaired in both scales. DIAPS's domains correlated similarly with the EQ-5D-3L and 5L scales' individual domains. Female sex, medical disorders, secondary APS and type of presenting thrombosis (arterial) increased the risk of HR-QoL impairment. Total DIAPS was associated with higher odds of mobility, self-care and pain/discomfort impairment in both EQ-5D-3L and 5L scales but lost its independent risk in multivariable analysis.Conclusion This external validation of DIAPS reinforces the ability of the score to correlate with HR-QoL while also highlighting risk factors for HR-QoL impairment other than damage accrual.
引用
收藏
页码:716 / 727
页数:12
相关论文
共 40 条
  • [1] Development and initial validation of a damage index (DIAPS) in patients with thrombotic antiphospholipid syndrome (APS)
    Amigo, M-C
    Goycochea-Robles, M. V.
    Espinosa-Cuervo, G.
    Medina, G.
    Barragan-Garfias, J. A.
    Vargas, A.
    Jara, L. Javier
    [J]. LUPUS, 2015, 24 (09) : 927 - 934
  • [2] Damage measured by Damage Index for Antiphospholipid Syndrome (DIAPS) in antiphospholipid antibody-positive patients included in the APS ACTION registry
    Balbi, Gustavo G. M.
    Ahmadzadeh, Yasaman
    Tektonidou, Maria G.
    Pengo, Vittorio
    Sciascia, Savino
    Ugarte, Amaia
    Belmont, H. Michael
    Lopez-Pedrera, Chary
    Fortin, Paul R.
    Wahl, Denis
    Gerosa, Maria
    de Jesus, Guilherme R.
    Ji, Lanlan
    Atsumi, Tatsuya
    Efthymiou, Maria
    Branch, D. Ware
    Nalli, Cecilia
    Rodriguez Almaraz, Esther
    Petri, Michelle
    Cervera, Ricard
    Knight, Jason S.
    Artim-Esen, Bahar
    Willis, Rohan
    Bertolaccini, Maria Laura
    Cohen, Hannah
    Roubey, Robert
    Erkan, Doruk
    Oliveira de Andrade, Danieli Castro
    [J]. RHEUMATOLOGY, 2024, 63 (03) : 772 - 779
  • [3] Thrombovascular Events Affect Quality of Life in Patients with Systemic Lupus Erythematosus
    Balitsky, Amaris K.
    Peeva, Valentina
    Su, Jiandong
    Aghdassi, Elaheh
    Yeo, Eric
    Gladman, Dafna D.
    Urowitz, Murray B.
    Fortin, Paul R.
    [J]. JOURNAL OF RHEUMATOLOGY, 2011, 38 (06) : 1017 - 1019
  • [4] Bolen J., 2010, NAT HLTH INT SURV, V7
  • [5] Carpenter Delesha M, 2011, Open Rheumatol J, V5, P24, DOI 10.2174/1874312901105010024
  • [6] Morbidity and mortality in the antiphospholipid syndrome during a 10-year period: a multicentre prospective study of 1000 patients
    Cervera, R.
    Serrano, R.
    Pons-Estel, G. J.
    Ceberio-Hualde, L.
    Shoenfeld, Y.
    de Ramon, E.
    Buonaiuto, V.
    Jacobsen, S.
    Zeher, M. M.
    Tarr, T.
    Tincani, A.
    Taglietti, M.
    Theodossiades, G.
    Nomikou, E.
    Galeazzi, M.
    Bellisai, F.
    Meroni, P. L.
    Derksen, R. H. W. M.
    de Groot, P. G. D.
    Baleva, M.
    Mosca, M.
    Bombardieri, S.
    Houssiau, F.
    Gris, J-C
    Quere, I.
    Hachulla, E.
    Vasconcelos, C.
    Fernandez-Nebro, A.
    Haro, M.
    Amoura, Z.
    Miyara, M.
    Tektonidou, M.
    Espinosa, G.
    Bertolaccini, M. L.
    Khamashta, M. A.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2015, 74 (06) : 1011 - 1018
  • [7] Impact of disease activity on health-related quality of life in systemic lupus erythematosus-a cross-sectional analysis of the Swiss Systemic Lupus Erythematosus Cohort Study (SSCS)
    Chaigne, Benjamin
    Chizzolini, Carlo
    Perneger, Thomas
    Trendelenburg, Marten
    Huynh-Do, Uyen
    Dayer, Eric
    Stoll, Thomas
    von Kempis, Johannes
    Ribi, Camillo
    [J]. BMC IMMUNOLOGY, 2017, 18
  • [8] Identification of high thrombotic risk triple-positive antiphospholipid syndrome patients is dependent on anti-cardiolipin and anti-β2glycoprotein I antibody detection assays
    Chayoua, W.
    Kelchtermans, H.
    Moore, G. W.
    Musial, J.
    Wahl, D.
    de Laat, B.
    Devreese, K. M. J.
    [J]. JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2018, 16 (10) : 2016 - 2023
  • [9] Cohen H, 2020, LANCET HAEMATOL, V7, pE613, DOI 10.1016/S2352-3026(20)30116-2
  • [10] Rivaroxaban versus warfarin to treat patients with thrombotic antiphospholipid syndrome, with or without systemic lupus erythematosus (RAPS): a randomised, controlled, open-label, phase 2/3, non-inferiority trial
    Cohen, Hannah
    Hunt, Beverley J.
    Efthymiou, Maria
    Arachchillage, Deepa R. J.
    Mackie, Ian J.
    Clawson, Simon
    Sylvestre, Yvonne
    Machin, Samuel J.
    Bertolaccini, Maria L.
    Ruiz-Castellano, Maria
    Muirhead, Nicola
    Dore, Caroline J.
    Khamashta, Munther
    Isenberg, David A.
    [J]. Lancet Haematology, 2016, 3 (09): : E426 - E436